Premium
Lansoprazole enhances the antidiabetic effect of dapagliflozin in fortified diet‐fed streptozotocin‐treated diabetic rats
Author(s) -
Gamil Noha M.,
Abd El Fattah Mai A.,
Ahmed Maha A. E.,
Maklad Yousreya A.,
Gamal el Din Amina A.,
Eid Nihad I.
Publication year - 2020
Publication title -
journal of biochemical and molecular toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.526
H-Index - 58
eISSN - 1099-0461
pISSN - 1095-6670
DOI - 10.1002/jbt.22451
Subject(s) - lansoprazole , dapagliflozin , streptozotocin , diabetes mellitus , medicine , insulin resistance , pharmacology , type 2 diabetes , endocrinology , omeprazole
Dapagliflozin (DAPA) is used for treating type 2 diabetes, whereas lansoprazole (LPZ) is used as a traditional antiulcer drug. The present study investigated the possible antidiabetic effects of LPZ on fortified diet‐fed streptozotocin (FDF/STZ)‐induced insulin‐resistant diabetic rats. On the basis of the current results, it can be concluded that LPZ could be used as an add‐on drug along with the conventional treatment for T2D as it showed beneficial effects in the current experimental model of insulin resistance.